View More Recent Stories

May 21, 2025 12:18PM UroGen Pharma (URGN): FDA ODAC voted 4 to 5 that benefit/risk of UGN-102 for intravesical solution was favorable for treatment of recurrent LG-IR-NMIBC
May 21, 2025 06:59AM UroGen Pharma (URGN) Halted, News Pending
May 16, 2025 12:22PM UroGen Pharma (URGN) FDA Briefing Docs 'Give Us Pause' - Oppenheimer
May 16, 2025 09:13AM UroGen Pharma (URGN) Falls 6% After FDA Released Docs Ahead Of May 21 Panel
May 12, 2025 08:02AM UroGen Pharma (URGN) Misses Q1 EPS by 13c
May 7, 2025 08:57AM UroGen Pharma (URGN) Announces FDA Advisory Committee for UGN-102
Mar 11, 2025 09:47AM UroGen Pharma (URGN) PT Lowered to $36 at Raymond James
Mar 11, 2025 06:42AM UroGen Pharma (URGN) PT Lowered to $55 at H.C. Wainwright
Mar 10, 2025 08:03AM UroGen Pharma (URGN) Misses Q4 EPS by 3c
Feb 25, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Feb 20, 2025 08:02AM UroGen Pharma (URGN) Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Feb 14, 2025 02:30PM UroGen Pharma (URGN) Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Feb 12, 2025 08:02AM UroGen Pharma (URGN): Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Publ
Jan 22, 2025 08:04AM UroGen Pharma (URGN) New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate
Jan 15, 2025 08:05AM UroGen Pharma (URGN): ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months
Dec 5, 2024 03:31PM UroGen Pharma (URGN) Presents Data from Long-Term Follow-up Study to the OLYMPUS Trial
Dec 5, 2024 03:22PM UroGen Pharma (URGN): UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial
Nov 26, 2024 08:02AM UroGen Pharma (URGN) Reports New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO
Nov 6, 2024 08:03AM UroGen Pharma (URGN) Tops Q3 EPS by 27c
Oct 16, 2024 06:14AM Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN), 'reiterate URGN as a top pick'
Oct 15, 2024 04:31PM UroGen Pharma (URGN) Announces FDA Acceptance of its NDA for UGN-102
Oct 15, 2024 06:33AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Oct 14, 2024 07:14AM EF Hutton Starts UroGen Pharma (URGN) at Buy
Oct 9, 2024 08:01AM UroGen Pharma (URGN) Appoints Chris Degnan as CFO
Oct 3, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Sep 18, 2024 05:53AM Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN), 'top pick and regard current levels as attractive ahead of upcoming newsflow'
Sep 16, 2024 08:02AM UroGen Pharma (URGN) Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
Aug 16, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Aug 14, 2024 08:00AM UroGen Pharma (URGN) Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Aug 13, 2024 04:09PM Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
Aug 13, 2024 02:10PM TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
Aug 13, 2024 08:02AM UroGen Pharma (URGN) Misses Q2 EPS by 8c
Jul 23, 2024 09:19AM TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
Jul 1, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Jun 17, 2024 04:47PM UroGen Pharma (URGN) Commences Share and Warrant Offering
Jun 14, 2024 06:54AM UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
Jun 14, 2024 06:35AM UroGen Pharma (URGN) PT Raised to $60 at H.C. Wainwright
Jun 14, 2024 05:11AM Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
Jun 13, 2024 02:21PM TD Cowen Reiterates Buy Rating on UroGen Pharma (URGN)
Jun 13, 2024 10:56AM UroGen Pharma (URGN) option IV into data
Jun 13, 2024 10:45AM UroGen (URGN) Announces 82.3% Duration of Response at 12 Months in ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Jun 13, 2024 10:40AM UroGen Pharma (URGN) Halted, News Pending
View More Recent Stories